Azitra, Inc. (NYSEAMERICAN:AZTR – Free Report) – Analysts at Zacks Research upped their FY2026 EPS estimates for Azitra in a research note issued on Friday, May 22nd. Zacks Research analyst J. Vandermosten now expects that the company will post earnings of ($0.25) per share for the year, up from their previous estimate of ($0.71). The consensus estimate for Azitra’s current full-year earnings is ($0.71) per share. Zacks Research also issued estimates for Azitra’s FY2027 earnings at ($0.08) EPS.
Azitra Stock Performance
Shares of NYSEAMERICAN AZTR opened at $0.21 on Thursday. The firm has a 50 day moving average of $0.22 and a 200 day moving average of $0.26. Azitra has a 12-month low of $0.10 and a 12-month high of $2.40.
Azitra Company Profile
Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.
The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.
Further Reading
- Five stocks we like better than Azitra
- Dick’s Sporting Goods Isn’t Done Winning Yet
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
